Profile and investment
| Fund type | Open Ended Investment Company |
|---|---|
| Investment style (stocks) | Market Cap: Large Investment Style: Value |
| Morningstar category | Foreign Large Value |
| Launch date | 16 Mar 2020 |
| Price currency | USD |
| Domicile | United States |
| Symbol | TROZX |
| Manager & start date | Colin McQueen 01 Jul 2019 |
| Pricing frequency | Daily |
|---|---|
| Total net assets | 18.04bn USD As of Jan 31 2026 |
| Share class size | 13.88bn USD As of Jan 31 2026 |
| Net expense ratio | 0.00% |
| Front end load | -- |
| Deferred load | -- |
| Maximum Redemption Fee | -- |
| Min. initial investment | 0.00 USD |
| Min. additional investment | -- |
| Initial IRA | -- |
| Additional IRA | -- |
| Available for sale | United States |
More ▼
Top 5 holdings
| Top 5 holdings as a per cent of portfolio | |||
|---|---|---|---|
| 13.30% | 9.99% | 0.00% | 9.99% |
| Category average | % Net assets | % Short | % Long |
| Company | 1 year change | Portfolio weight | Long allocation |
|---|---|---|---|
| Rolls-Royce Holdings PLC RR.:LSE | +107.81% | 2.34% | |
| AstraZeneca PLC ADR | -- | 2.19% | |
| UniCredit SpA UCG:MIL | +53.05% | 1.98% | |
| Samsung Electronics Co Ltd | +224.73% | 1.89% | |
| Roche Holding AG ROG:SWX | +22.72% | 1.59% | |
| Per cent of portfolio in top 5 holdings: 9.99% |
Asset type
| Non-US stock | 95.84% |
| Cash | 2.31% |
| US stock | 1.85% |
| US bond | 0.00% |
| Non-US bond | 0.00% |
| Other | 0.00% |
Top 5 sectors
| Financial Services | 29.51% |
| Industrials | 14.91% |
| Healthcare | 9.78% |
| Consumer Cyclical | 8.61% |
| Technology | 7.03% |
| Other | 27.85% |
Top 5 regions
| Eurozone | 37.18% |
| United Kingdom | 21.70% |
| Japan | 16.72% |
| Developed Asia | 7.81% |
| Europe - ex Euro | 4.92% |
| Other | 9.36% |
Sector and region weightings are calculated using only long position holdings of the portfolio.
